Search

Your search keyword '"Nomdedeu, Josep"' showing total 8 results
Start Over Author "Nomdedeu, Josep" Journal haematologica
8 results on '"Nomdedeu, Josep"'

1. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

Author

Marin-Bejar, Oskar, primary, Romero-Moya, Damia, additional, Rodriguez-Ubreva, Javier, additional, Distefano, Maximiliano, additional, Lessi, Francesca, additional, Aretini, Paolo, additional, Liquori, Alessandro, additional, Castaño, Julio, additional, Kozyra, Emilia, additional, Kotmayer, Lili, additional, Bueno, Clara, additional, Cervera, José, additional, Rodriguez-Gallego, José Carlos, additional, Nomdedeu, Josep F, additional, Murillo-Sanjuán, Laura, additional, De Heredia, Cristina Díaz, additional, Pérez-Martinez, Antonio, additional, López-Cadenas, Félix, additional, Martínez-Laperche, Carolina, additional, Dorado-Herrero, Nieves, additional, Marco, Francisco M, additional, Prósper, Felipe, additional, Menendez, Pablo, additional, Valcárcel, David, additional, Ballestar, Esteban, additional, Bödör, Csaba, additional, Bigas, Anna, additional, Catalá, Albert, additional, Wlodarski, Marcin W, additional, and Giorgetti, Alessandra, additional

Published
2023
Full Text
View/download PDF

2. RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing

Author

Gu, Muxin, primary, Zwiebel, Maximillian, additional, Ong, Swee Hoe, additional, Boughton, Nick, additional, Nomdedeu, Josep, additional, Basheer, Faisal, additional, Nannya, Yasuhito, additional, Quiros, Pedro M., additional, Ogawa, Seishi, additional, Cazzola, Mario, additional, Rad, Roland, additional, Butler, Adam P., additional, Vijayabaskar, MS, additional, and Vassiliou, George S., additional

Published
2019
Full Text
View/download PDF

3. Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis

Author

de la Guardia, Rafael Diaz, primary, Lopez-Millan, Belen, additional, Roca-Ho, Heleia, additional, Bueno, Clara, additional, Gutiérrez-Agüera, Francisco, additional, Fuster, Jose Luis, additional, Anguita, Eduardo, additional, Zanetti, Samanta Romina, additional, Vives, Susana, additional, Nomdedeu, Josep, additional, Sackstein, Robert, additional, Lavoie, Jessie, additional, Gónzalez-Rey, Elena, additional, Delgado, Mario, additional, Rosu-Myles, Michael, additional, and Menendez, Pablo, additional

Published
2018
Full Text
View/download PDF

4. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

Author

Onecha, Esther, primary, Linares, Maria, additional, Rapado, Inmaculada, additional, Ruiz-Heredia, Yanira, additional, Martinez-Sanchez, Pilar, additional, Cedena, Teresa, additional, Pratcorona, Marta, additional, Oteyza, Jaime Perez, additional, Herrera, Pilar, additional, Barragan, Eva, additional, Montesinos, Pau, additional, Vela, Jose Antonio Garcia, additional, Magro, Elena, additional, Anguita, Eduardo, additional, Figuera, Angela, additional, Riaza, Rosalia, additional, Martinez-Barranco, Pilar, additional, Sanchez-Vega, Beatriz, additional, Nomdedeu, Josep, additional, Gallardo, Miguel, additional, Martinez-Lopez, Joaquin, additional, and Ayala, Rosa, additional

Published
2018
Full Text
View/download PDF

6. Bone marrow mesenchymal stem/stromal cells from risk-stratified acute myeloid leukemia patients are anti-inflammatory in in vivo preclinical models of hematopoietic reconstitution and severe colitis.

Author

de la Guardia RD, Lopez-Millan B, Roca-Ho H, Bueno C, Gutiérrez-Agüera F, Fuster JL, Anguita E, Zanetti SR, Vives S, Nomdedeu J, Sackstein R, Lavoie J, Gónzalez-Rey E, Delgado M, Rosu-Myles M, and Menendez P

Subjects
Animals, Colitis diagnosis, Colitis etiology, Disease Models, Animal, Humans, Leukemia, Myeloid, Acute, Mesenchymal Stem Cells cytology, Mice, Severity of Illness Index, Treatment Outcome, Colitis therapy, Hematopoiesis, Mesenchymal Stem Cell Transplantation adverse effects, Mesenchymal Stem Cell Transplantation methods, Mesenchymal Stem Cells metabolism
Published
2019
Full Text
View/download PDF

7. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

Author

Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Oteyza JP, Herrera P, Barragan E, Montesinos P, Vela JAG, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, and Ayala R

Subjects
Adult, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Nucleophosmin, Polymorphism, Single Nucleotide, Prognosis, Proportional Hazards Models, Workflow, Biomarkers, Tumor, High-Throughput Nucleotide Sequencing, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Neoplasm, Residual diagnosis, Neoplasm, Residual genetics
Abstract

A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1 , IDH1/2 and/or FLT3 -single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10 -4 for single nucleotide variants and 10 -5 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P =0.005) and lower overall survival (hazard ratio 4.2, P <0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P =0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P =0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials., (Copyright © 2019 Ferrata Storti Foundation.)

Published
2019
Full Text
View/download PDF

8. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.

Author

Lasa A, Carricondo MT, Carnicer MJ, Perea G, Aventín A, and Nomdedeu JF

Subjects
Genes, Neoplasm genetics, Humans, Prognosis, RUNX1 Translocation Partner 1 Protein, Spain, Core Binding Factor Alpha 2 Subunit, Leukemia, Myeloid genetics, Mutation, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-kit genetics
Abstract

One of the most common genetic events in acute myeloid leukemia (AML) is the t(8;21) (q22;q22) translocation, which contributes to leukemic transformation. However, different lines of evidence suggest that the AML1-ETO rearrangement is not sufficient to cause the full leukemic phenotype. Secondary genetic alterations such as mutations in receptor tyrosine kinases are thus required to induce overt AML. The incidence of c-KIT mutations in exon 17 was evaluated in 37 Spanish patients with AML1-ETO+ leukemias. c-KIT mutations were present in only two cases (6.6%) and were shown to be associated with an adverse outcome. The frequency of c-KIT mutations described here is much lower than in other reports.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results